A Phase 1 interventional study of Norethindrone/Ethinyl Estradiol and FEMCON® Fe in Healthy, sponsored by Teva Pharmaceuticals USA. Completed at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-05-30.
Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study was to evaluate the relative bioavailability of a test formulation of norethindrone/ethinyl estradiol 0.4 mg/0.035 mg chewable tablets (Teva Pharmaceuticals, USA) compared to the reference listed product, FEMCON® Fe (norethindrone/ethinyl estradiol and ferrous fumarate) 0.4 mg/0.035 mg Chewable tablets (Warner Chilcott) under fed conditions in healthy, non-tobacco using, adult female subjects.
Teva Pharmaceuticals USA is the lead sponsor of 176 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Norethindrone/Ethinyl Estradiol 0.4 mg/0.035 mg Chewable Tablets (Teva)
Drug: Norethindrone/Ethinyl Estradiol
FEMCON® Fe 0.4 mg/0.035 mg Chewable tablets (Warner Chilcott)
Drug: FEMCON® Fe
Drug pages: Norethindrone · Ethinyl Estradiol
0.4 mg/0.035 mg Chewable Tablets
Also known as: Zeosa®
0.4 mg/0.035 mg Chewable Tablets
Also known as: Ovcon® 35 Fe, norethindrone/ethinyl estradiol (generic name)
Cmax of Norethindrone
Bioequivalence based on Norethindrone Cmax (maximum observed concentration of drug substance in plasma).
Time frame: Blood samples collected over a 60 hour period.
AUC0-t of Norethindrone
Bioequivalence based on Norethindrone AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).
Time frame: Blood samples collected over a 60 hour period.
AUC0-inf of Norethindrone
Bioequivalence based on Norethindrone AUC0-inf (area under the concentration-time curve from time zero to infinity).
Time frame: Blood samples collected over a 60 hour period.
Cmax of Ethinyl Estradiol
Bioequivalence based on Ethinyl Estradiol Cmax (maximum observed concentration of drug substance in plasma).
Time frame: Blood samples collected over a 60 hour period.
AUC0-t of Ethinyl Estradiol
Bioequivalence based on Ethinyl Estradiol AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).
Time frame: Blood samples collected over a 60 hour period.
AUC0-inf of Ethinyl Estradiol
Bioequivalence based on Ethinyl Estradiol AUC0-inf (area under the concentration-time curve from time zero to infinity).
Time frame: Blood samples collected over a 60 hour period.
| Milestone | Norethindrone/Ethinyl Estradiol (Test) First | FEMCON® Fe (Reference) First |
|---|---|---|
| Started | 18 | 18 |
| Completed | 18 | 18 |
| Not completed | 0 | 0 |
| Milestone | Norethindrone/Ethinyl Estradiol (Test) First | FEMCON® Fe (Reference) First |
|---|---|---|
| Started | 18 | 18 |
| Completed | 17 | 17 |
| Not completed | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 |
| Milestone | Norethindrone/Ethinyl Estradiol (Test) First | FEMCON® Fe (Reference) First |
|---|---|---|
| Started | 17 | 17 |
| Completed | 17 | 16 |
| Not completed | 0 | 1 |
| Withdrew: Emesis within 2 x tmax | 0 | 1 |
Bioequivalence based on Norethindrone Cmax (maximum observed concentration of drug substance in plasma).
| ng/mL | Norethindrone/Ethinyl Estradiol (Test) | FEMCON® Fe (Reference) |
|---|---|---|
| Cmax of Norethindrone | 4.3306 ± 1.7393 | 4.2282 ± 1.6696 |
Bioequivalence based on Norethindrone AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).
| ng*h/mL | Norethindrone/Ethinyl Estradiol (Test) | FEMCON® Fe (Reference) |
|---|---|---|
| AUC0-t of Norethindrone | 37.8065 ± 16.1921 | 37.3991 ± 15.3939 |
Bioequivalence based on Norethindrone AUC0-inf (area under the concentration-time curve from time zero to infinity).
| ng*h/mL | Norethindrone/Ethinyl Estradiol (Test) | FEMCON® Fe (Reference) |
|---|---|---|
| AUC0-inf of Norethindrone | 43.9982 ± 19.4559 | 43.8819 ± 18.8478 |
Bioequivalence based on Ethinyl Estradiol Cmax (maximum observed concentration of drug substance in plasma).
| pg/mL | Norethindrone/Ethinyl Estradiol (Test) | FEMCON® Fe (Reference) |
|---|---|---|
| Cmax of Ethinyl Estradiol | 137.6758 ± 33.6231 | 137.8485 ± 37.6177 |
Bioequivalence based on Ethinyl Estradiol AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).
| pg*h/mL | Norethindrone/Ethinyl Estradiol (Test) | FEMCON® Fe (Reference) |
|---|---|---|
| AUC0-t of Ethinyl Estradiol | 1916.2311 ± 433.4875 | 1987.6311 ± 478.7842 |
Bioequivalence based on Ethinyl Estradiol AUC0-inf (area under the concentration-time curve from time zero to infinity).
| pg*h/mL | Norethindrone/Ethinyl Estradiol (Test) | FEMCON® Fe (Reference) |
|---|---|---|
| AUC0-inf of Ethinyl Estradiol | 2072.5423 ± 483.0176 | 2152.3775 ± 517.5977 |
Collected over Adverse event data was collected over the course of the study, which was approximately 6 weeks in duration.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Norethindrone/Ethinyl Estradiol (Test) | — | 0/36 (0%) | 13/36 (36.1%) |
| FEMCON® Fe (Reference) | — | 0/36 (0%) | 10/36 (27.8%) |
| Event | Norethindrone/Ethinyl Estradiol (Test) | FEMCON® Fe (Reference) |
|---|---|---|
| NauseaGeneral disorders | 6/36 | 3/36 |
| VomitingGeneral disorders | 5/36 | 3/36 |
| HeadacheGeneral disorders | 5/36 | 1/36 |
| Abdominal CrampingGeneral disorders | 4/36 | 0/36 |
| Sinus CongestionGeneral disorders | 0/36 | 2/36 |
| Decreased Blood PressureGeneral disorders | 2/36 | 2/36 |
| Increased TemperatureGeneral disorders | 0/36 | 2/36 |
| Increased Blood PressureGeneral disorders | 1/36 | 2/36 |
| Age, Categorical(Participants) | Norethindrone/Ethinyl Estradiol (Test) First | FEMCON® Fe (Reference) First | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 18 | 18 | 36 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Norethindrone/Ethinyl Estradiol (Test) First | FEMCON® Fe (Reference) First | Total |
|---|---|---|---|
| Female | 18 | 18 | 36 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Norethindrone/Ethinyl Estradiol (Test) First | FEMCON® Fe (Reference) First | Total |
|---|---|---|---|
| Black | 12 | 14 | 26 |
| Caucasian | 2 | 1 | 3 |
| Hispanic | 4 | 3 | 7 |
| Region of Enrollment(participants) | Norethindrone/Ethinyl Estradiol (Test) First | FEMCON® Fe (Reference) First | Total |
|---|---|---|---|
| United States | 18 | 18 | 36 |
The record gives a start of Aug 2008, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Norethindrone · Ethinyl Estradiol